The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with non-small cell lung cancer.
Treatment of advanced non-small cell lung cancer (NSCLC) has rapidly evolved with the availability of immune checkpoint inhibitor (ICI) therapy. The integration of immunotherapy into treatment protocols offers the potential for durable treatment responses and improved survival for patients with tumors that lack targetable molecular alterations. As increased long-term data become available on the safety and efficacy of ICI therapy, evidence is emerging on novel immunotherapy combinations that may further improve patient outcomes in advanced NSCLC. In this CME activity, participants will play GameOn!, an interactive quiz of knowledge and confidence, in which they answer questions on long-term outcomes with immunotherapy, novel treatment combinations, and emerging agents. Through this gaming activity, faculty offer insight into current best practices and emerging approaches using ICIs for first-line therapy of advanced NSCLC and treatment of progressive disease.
Upon completion of this activity, participants should be better able to: